Novavax, Inc.
NVAX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $682 | $556 | $1,599 | $198 |
| % Growth | 22.6% | -65.2% | 709.3% | – |
| Cost of Goods Sold | $203 | $344 | $903 | $0 |
| Gross Profit | $479 | $213 | $696 | $198 |
| % Margin | 70.3% | 38.2% | 43.5% | 100% |
| R&D Expenses | $391 | $738 | $1,235 | $2,535 |
| G&A Expenses | $0 | $0 | $489 | $298 |
| SG&A Expenses | $337 | $469 | $489 | $298 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$427 | -$383 | -$949 |
| Operating Expenses | $728 | $779 | $1,341 | $1,884 |
| Operating Income | -$249 | -$567 | -$645 | -$1,687 |
| % Margin | -36.5% | -101.8% | -40.3% | -853.6% |
| Other Income/Exp. Net | $72 | $23 | -$9 | -$28 |
| Pre-Tax Income | -$177 | -$543 | -$654 | -$1,715 |
| Tax Expense | $11 | $2 | $4 | $29 |
| Net Income | -$187 | -$545 | -$658 | -$1,744 |
| % Margin | -27.5% | -98% | -41.1% | -882.5% |
| EPS | -1.23 | -5.41 | -8.42 | -23.44 |
| % Growth | 77.3% | 35.7% | 64.1% | – |
| EPS Diluted | -1.23 | -5.41 | -8.42 | -23.44 |
| Weighted Avg Shares Out | 152 | 101 | 78 | 74 |
| Weighted Avg Shares Out Dil | 152 | 101 | 78 | 74 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $20 | $14 | $20 | $21 |
| Depreciation & Amortization | $48 | $41 | $29 | $13 |
| EBITDA | -$108 | -$487 | -$605 | -$1,681 |
| % Margin | -15.8% | -87.6% | -37.8% | -850.7% |